Immunome's Varegacestat Meets Phase 3 Endpoint in Desmoid Tumor Treatment: Key Data Release Today

2025-12-26 04:08:50

Abstract generation in progress

Immunome, Inc. (IMNM) announced the release of topline results from the RINGSIDE trial—a pivotal Phase 3 study evaluating Varegacestat as a treatment for desmoid tumors. The trial enrolled 156 patients aged 12 and older with progressive desmoid tumors in this placebo-controlled study. This marks a significant milestone for the company’s lead oncology asset.

Understanding Desmoid Tumors and the Therapeutic Approach

Desmoid tumors represent a class of rare, locally invasive soft tissue neoplasms that, although non-metastatic in nature, frequently result in considerable patient morbidity. The limited availability of effective therapeutic options underscores the clinical need for innovative targeted treatments. Varegacestat operates by inhibiting gamma secretase—an enzyme fundamentally involved in desmoid tumor pathogenesis. This gamma-secretase inhibition mechanism targets the underlying biological pathway driving tumor progression, distinguishing it from conventional treatment approaches.

Immunome’s Expanding Clinical Pipeline

Beyond Varegacestat, Immunome has assembled a robust portfolio of next-generation targeted oncology programs:

IM-1021 represents a ROR1-targeted antibody-drug conjugate incorporating the company’s proprietary HC74 payload, currently advancing through Phase 1 with initial lymphoma data anticipated in 2026.

IM-3050, a FAP-targeted radiopharmaceutical, recently secured IND clearance with Phase 1 initiation scheduled for early 2026.

HC74 Payload functions as a novel topoisomerase I inhibitor engineered to overcome multi-drug resistance mechanisms. Preclinical studies demonstrated efficacy against trastuzumab-DXd refractory colorectal cancer, NSCLC with heterogeneous target expression, and additional resistant tumor models.

The company is also advancing a suite of HC74-based ADC candidates—IM-1617, IM-1340, and IM-1335—targeting undisclosed solid tumors, with these programs progressing toward IND submission.

Financial Position and Stock Performance

As of September 30, 2025, Immunome maintains a cash position of $272.6 million, providing operational runway extending into 2027. Over the past 12 months, IMNM shares have traded within a range of $5.15 to $20.80. The stock closed Friday’s session at $19.57, representing a 0.41% increase, and subsequently rose to $20.49 in after-hours trading, reflecting a 4.70% gain.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.